Short Interest in Euroapi S.A. (OTCMKTS:EAPIF) Increases By 73.1%

Euroapi S.A. (OTCMKTS:EAPIF) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 42,983 shares, a growth of 73.1% from the March 15th total of 24,828 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Euroapi Price Performance

Euroapi stock opened at C$1.55 on Monday. Euroapi has a 1-year low of C$1.27 and a 1-year high of C$3.74. The business has a fifty day moving average price of C$1.90 and a 200-day moving average price of C$2.73.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Euroapi in a research report on Thursday, January 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Euroapi presently has a consensus rating of “Sell”.

About Euroapi

Euroapi is a standalone global active pharmaceutical ingredient (API) company formed in 2022 following its spin-off from the API division of a major multinational pharmaceutical group. The company focuses on the development, manufacturing and supply of a broad range of small-molecule APIs used in prescription drugs, over-the-counter products and vaccines. Its portfolio encompasses core areas such as semi-synthetic antibiotics (notably penicillins and cephalosporins), APIs for oncology, central nervous system disorders and cardiovascular therapies, as well as niche specialty ingredients.

Since its inception, Euroapi has pursued a growth strategy centered on innovation, capacity expansion and long-term partnerships with pharmaceutical customers.